JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105
JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.
Read original at benzingaStocks · News reference
Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says
Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 24, 2026, 3:48 PM
- Checked
- Jul 24, 2026, 3:48 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101
Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.
Read original at benzingaEdwards Lifesciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
Read original at benzinga